Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ALN-62643----[2] 62, 109 💬
2ALN-CC5----[4] 11, 62, 66, 109 💬
3ALXN1210----[7] 2, 11, 13, 50, 62, 66, 109 💬
4Anti-C5 antibody----[4] 11, 14, 62, 109 💬
5C5 inh MAb, SKY59, RO/CH7092230----[2] 62, 109 💬
6CCX168----[5] 43, 44, 66, 109, 222 💬
7Cemdisiran[1] Cemdisiran---[4] 11, 62, 66, 109 💬
8COVERSIN[1] Nomacopan[1] Nomacopan 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[2] 62, 109 💬
9CROVALIMAB[1] Crovalimab[1] Crovalimab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[2] 62, 109 💬
10ECULIZUMAB[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 11, 13, 14, 61, 62, 109, 222 💬
11Fc- and CDR-modified humanised monoclonal antibody against C5----[3] 11, 62, 109 💬
12IgG2/4?----[1] 109 💬
13Iptacopan[1] Iptacopan[1] Iptacopan 💬 [1] CFB 💬 [3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[5] 61, 62, 66, 109, 222 💬
14LNP023----[5] 61, 62, 66, 109, 222 💬
15MASP-2 antibody[1] Narsoplimab[1] Narsoplimab 💬 [1] MASP2 💬 [3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[3] 64, 66, 109 💬
16NM8074----[2] 62, 109 💬
17OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] Narsoplimab 💬 [1] MASP2 💬 [3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[1] 109 💬
18OMS721----[3] 64, 66, 109 💬
19OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] Narsoplimab 💬 [1] MASP2 💬 [3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[2] 64, 109 💬
20OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] Narsoplimab 💬 [1] MASP2 💬 [3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[2] 64, 109 💬
21OMS721 Drug Product 185 mg/mL----[1] 109 💬
22RAVULIZUMAB[1] Ravulizumab[1] Ravulizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 2, 11, 13, 50, 62, 66, 109 💬
23RO7112689/F03-01----[2] 62, 109 💬
24RO7112689/F03-10----[2] 62, 109 💬
25RVA576----[3] 62, 109, 162 💬
26RVA576 (COVERSIN)[1] Nomacopan[1] Nomacopan 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[2] 62, 109 💬
27Solaris----[2] 62, 109 💬
28SOLIRIS[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 11, 13, 14, 61, 62, 109, 222 💬
29SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[3] 13, 62, 109 💬
30SOLIRIS 300 mg concentrado para solución para perfusión[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 109 💬
31 LNP023 HYDROCHLORIDE SALT----[5] 61, 62, 66, 109, 222 💬